Uncategorized

At ImmunoServ we are on a mission to bring T cell testing to the masses. The World’s first At-Home COVID-19 T cell test is now available to anyone in the United Kingdom. People who wish to test their own T cell immune response to COVID-19 using Immuno-T^TM, can visit our Immuno-T website.

ImmunoServ is proud to announce that it has obtained the UKCA (UK Conformity Assessed) mark for its Immuno-T At Home Blood Collection Kit.

In January 2022 ImmunoServ launched its trial of the Worlds first At-Home combined COVID-19 T cell and antibody test. Participants from across the UK were invited to sign up to the validation study. Within 10 weeks more than 300 participants have been recruited.

ImmunoServ is pleased to announce the appointment of Dr James Hindley as our new Chief Executive Officer. James brings a wealth of immunology and entrepreneurial experience in guiding biotech ventures; his proven leadership in the field is an excellent fit for ImmunoServ’s mission to provide expert immunology services to the world.

ImmunoServ is delighted to announce that the company’s commitment to Quality Assurance and Cyber Security has been independently verified.

Following the WHOs announcement about the new SARS-CoV-2 Omicron variant of concern (VoC) on 26 November 2021, the team here at ImmunoServ have started working on a T cell immune response test for this variant. This rapid development demonstrates the flexibility of our T cell testing platform and the dedication of our company to help in the ongoing fight against COVID-19.

ImmunoServ have been featured by Cardiff University for our work on a test to measure both the T-cell and antibody response to SARS-CoV-2 in a single blood sample.

We are delighted to announce the incorporation of ImmunoServ Ltd., a specialist contract research organisation in the immunology sector.